SGLT2 Inhibitor Composition for Glycemic Control Without Beta-Cell Strain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidiabetic drugs for type 2 diabetes, such as metformin and sulfonylureas, provide limited glycemic control and are associated with long-term complications and cardiovascular risks, necessitating a need for more effective treatments that improve glycemic control, reduce cardiovascular morbidity, and have a safer profile.
Innovation Solution
A pharmaceutical composition comprising an SGLT2 inhibitor is administered to patients, which inhibits renal glucose reuptake, leading to decreased blood glucose levels, weight loss, and improved glycemic control without straining pancreatic beta cells, and addresses various metabolic disorders and complications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antidiabetic drugs (metformin, sulfonylureas) are used for glycemic control, then diabetes treatment is provided, but glycemic control is limited and cardiovascular risks increase
Solution Approach 1:
The patent employs SGLT2 inhibitors that work through a different mechanism of action compared to conventional drugs. Instead of affecting insulin secretion or sensitivity, SGLT2 inhibitors change the parameter of renal glucose reabsorption, promoting glucose excretion in urine. This parameter change achieves improved glycemic control with a favorable cardiovascular safety profile, resolving the contradiction between effectiveness and cardiovascular risks
Solution Approach 2:
The invention introduces an intermediary mechanism (SGLT2 inhibition at the renal level) that mediates glycemic control independently of pancreatic beta cells and insulin pathways. This intermediary approach bypasses the harmful effects associated with conventional drugs while maintaining effective glucose lowering, thus reducing cardiovascular risks
2Reliability
If intensive treatment with metformin, sulfonylureas or insulin is applied, then glycemic control is improved, but B-cell function deteriorates over time
Solution Approach 1:
The patent uses SGLT2 inhibitors as an intermediary mechanism that controls glucose levels through renal excretion rather than through pancreatic beta cell stimulation. This intermediary pathway spares B-cell function from deterioration, enabling long-term sustained glycemic control without the progressive loss of efficacy seen with conventional intensive treatments
Solution Approach 2:
The invention changes the therapeutic parameter from insulin-based mechanisms to renal glucose excretion. This parameter change fundamentally alters the long-term efficacy profile by avoiding B-cell exhaustion, thereby maintaining consistent glycemic control over extended treatment periods
3Reliability
If oral antidiabetic drugs are used conventionally, then diabetes treatment is provided, but dosing inconvenience and tolerability limitations occur
Solution Approach 1:
The patent employs SGLT2 inhibitors that offer simplified dosing regimens with once-daily administration and minimal food effect requirements. This parameter change in dosing frequency and conditions significantly improves ease of operation while maintaining reliable glycemic control effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The SGLT2 inhibitor composition effectively reduces blood glucose, prevents complications, improves insulin sensitivity, and treats conditions like diabetic nephropathy and obesity, while maintaining pancreatic beta-cell function and reducing cardiovascular risks.
Implementation Method 1
SGLT2 inhibitors represent a novel class of agents that are being developed for the treatment or improvement in glycemic control in patients with type 2 diabetes. Reuptake of filtered glucose across epithelial cells of the kidney proceeds via sodium-dependent glucose cotransporters (SGLTs). SGLT2-inhibition will partially inhibit the reuptake of glucose from the glomerular filtrate into the blood leading to a decrease in blood glucose concentrations and to glucosuria
Data Source
AI summary
The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.